Galmed (GLMD) Pharmaceuticals announced meaningful top-line results from Galmed’s AM-001 Study, a Phase 1 Bioavailability Study of Aramchol meglumine. The AM-001 study was designed to help identify the optimal doses for advancing Aramchol meglumine into the upcoming oncology Phase 2 studies planned for H1 2026. The study compared the relative BA of Aramchol meglumine granules to Aramchol free acid tablets in 30 healthy volunteers. The study results demonstrated that the BA of Aramchol from the Aramchol meglumine granules is considerably greater than that from Aramchol free acid tablets. The BA of 400mg and 200mg Aramchol meglumine granules were approximately 5-fold and 3-fold respectively, from that of the Aramchol free acid 300 mg tablets. To date, Galmed has successfully advanced Aramchol through six clinical trials (up to Phase 3) enrolling 661 patients, establishing both its overall excellent tolerability, safety and efficacy in treating NASH under the IND 505(b)1regulatory pathway. In addition, 82 healthy subjects to date have received Aramchol meglumine under a clinical trial application in the United Kingdom.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLMD:
- Galmed Pharmaceuticals Reports Promising Results from Aramchol Meglumine Study
- Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study
- Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers
- Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting
- Galmed Pharmaceuticals Reschedules Annual General Meeting Due to Lack of Quorum